BioSpace News Archive

Stevanato Group S.p.A. announced that it will issue financial results for the second quarter of 2022 on Thursday, August 4, 2022, at 6:30 a.m. Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. on Thursday, August 4, 2022 to discuss results.

Ligand Pharmaceuticals Incorporated will report second quarter 2022 financial results after the close of the U.S. financial markets on Monday, August 8, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

Immune Therapeutics, Inc. (OTC Pink: IMUN) (“Immune” or “IMUN”), is pleased to announce the appointment of Dr. Stephen “Steve” Wilson as Immune’s Chief Executive Officer (CEO), President, and interim Chief Financial Officer (CFO) effective July 19, 2022; he will continue to serve as a member of the Company’s Board of Directors.

Iovance Biotherapeutics, Inc. announced that on July 21, 2022, the Company approved the grant of inducement stock options covering an aggregate of 39,400 shares of Iovance’s common stock to 15 new non-executive employees.

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), today announced topline data for its Phase 1b CLEAR clinical study to evaluate the effect of intranasal REVTx-99b on nasal challenge allergen in participants with allergic rhinitis to rye grass pollen.

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma.

Provider and Payer Analysis Supports Potential Commercialization of Innovation Pharmaceutical’s Brilacidin as a Novel Oral Mucositis Drug Candidate.

PepGen Inc. (“PepGen”), a Boston-based clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Caroline Godfrey, Ph.D., one of PepGen’s scientific co-founders, to its Scientific Advisory Board.

Alimera Sciences, Inc. will launch ILUVIEN ® for non-infectious posterior uveitis in France, through its distribution partner, Horus Pharma S.A.S. (Horus).

Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the conditional marketing authorization (CMA) to include a booster dose of Spikevax.